Compare TWIN & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWIN | CHRS |
|---|---|---|
| Founded | 1918 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 367.7M | 159.1M |
| IPO Year | 1994 | 2014 |
| Metric | TWIN | CHRS |
|---|---|---|
| Price | $24.16 | $0.64 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 55.3K | ★ 1.6M |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | ★ 0.81% | N/A |
| EPS Growth | ★ 1428.57 | 472.00 |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $381,270,000.00 | N/A |
| Revenue This Year | $7.56 | $34.69 |
| Revenue Next Year | $8.00 | $70.40 |
| P/E Ratio | $103.33 | ★ N/A |
| Revenue Growth | ★ 11.90 | N/A |
| 52 Week Low | $14.22 | $0.73 |
| 52 Week High | $29.24 | $2.62 |
| Indicator | TWIN | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 46.70 | 32.51 |
| Support Level | $22.34 | N/A |
| Resistance Level | $24.52 | $1.53 |
| Average True Range (ATR) | 1.45 | 0.10 |
| MACD | -0.09 | -0.02 |
| Stochastic Oscillator | 36.15 | 6.37 |
Twin Disc Inc designs, manufactures and sells marine and heavy-duty off highway power transmission equipment. Its products are marine transmissions, azimuth drives, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, controls systems, and braking systems. The company sells its products to customers in the pleasure craft, commercial, and military marine markets, as well as in the energy and natural resources, government, military, and industrial markets. It has two reportable segments: manufacturing and distribution. It derives the maximum revenue from the manufacturing segment. Geographically, it operates in United States, Netherlands, Finland, China, Australia, Italy and Others.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.